📰 Ev Phase News
Ev Phase News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Ev Phase. Real-time updates on events, politics, business and more.
March 6, 2023
Three late-breaking presentations in vitiligo highlight new long-term data from the Phase 3 TRuE-V trials for Opzelura (ruxolitinib) cream and results from a Phase 2b study with povorcitinib (INCB54707)
August 24, 2022
Incyte (Nasdaq:INCY) today announced that multiple abstracts featuring data from its dermatology portfolio will be presented at the upcoming 2022 European Academy of Dermatology and Venereology (EADV)
August 24, 2022
24.08.2022 - Incyte (Nasdaq:INCY) today announced that multiple abstracts featuring data from its dermatology portfolio will be presented at the upcoming 2022 European Academy of Dermatology and Venereology (EADV) Congress, held September 7-10, 2022, in Milan ... Seite 1
March 18, 2022
New data on ruxolitinib cream (Opzelura) in vitiligo and atopic dermatitis will be presented, including 52-week results from the Phase 3 TRuE-V vitiligo program which will be featured as a late-breaking
March 18, 2022
18.03.2022 - Incyte (Nasdaq:INCY) today announced that multiple abstracts featuring data from its dermatology portfolio will be presented at the upcoming American Academy of Dermatology (AAD) Annual Meeting, held March 25-29, 2022, in Boston. New 52-week data ... Seite 1
November 2, 2021
INCY earnings call for the period ending September 30, 2021.